P
81.76
-1.32 (-1.59%)
| Previous Close | 83.08 |
| Open | 82.45 |
| Volume | 771,447 |
| Avg. Volume (3M) | 900,188 |
| Market Cap | 5,111,280,640 |
| Price / Earnings (TTM) | 123.88 |
| Price / Earnings (Forward) | 26.39 |
| Price / Sales | 24.46 |
| Price / Book | 7.72 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Protagonist Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.1
| Analyst Consensus | 1.5 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.10 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 117.00 (HC Wainwright & Co., 43.10%) | Buy |
| Median | 109.00 (33.32%) | |
| Low | 81.00 (JP Morgan, -0.93%) | Buy |
| Average | 105.50 (29.04%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 84.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Jan 2026 | 117.00 (43.10%) | Buy | 81.80 |
| Truist Securities | 05 Jan 2026 | 110.00 (34.54%) | Buy | 84.18 |
| Barclays | 17 Dec 2025 | 108.00 (32.09%) | Buy | 89.34 |
| 07 Nov 2025 | 88.00 (7.63%) | Buy | 79.54 | |
| Citigroup | 08 Dec 2025 | 115.00 (40.66%) | Buy | 90.25 |
| 10 Nov 2025 | 98.00 (19.86%) | Buy | 83.23 | |
| Citizens | 07 Nov 2025 | 102.00 (24.76%) | Buy | 79.54 |
| JP Morgan | 07 Nov 2025 | 81.00 (-0.93%) | Buy | 79.54 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALI ASIF | - | 83.08 | -46,203 | -3,838,545 |
| MOLINA ARTURO MD | - | 82.83 | -23,151 | -1,919,748 |
| PATEL DINESH V PH D | - | 82.90 | -54,273 | -4,490,093 |
| Aggregate Net Quantity | -123,627 | |||
| Aggregate Net Value ($) | -10,248,386 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 82.89 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | Officer | 27 Jan 2026 | Sell (-) | 5,000 | 83.08 | 415,400 |
| MOLINA ARTURO MD | Officer | 27 Jan 2026 | Option execute | 5,000 | - | - |
| ALI ASIF | Officer | 27 Jan 2026 | Sell (-) | 46,203 | 83.08 | 3,838,545 |
| ALI ASIF | Officer | 27 Jan 2026 | Option execute | 28,000 | - | - |
| PATEL DINESH V PH D | Officer | 27 Jan 2026 | Sell (-) | 4,068 | 83.08 | 337,969 |
| PATEL DINESH V PH D | Officer | 27 Jan 2026 | Option execute | 4,068 | - | - |
| MOLINA ARTURO MD | Officer | 26 Jan 2026 | Sell (-) | 5,000 | 82.30 | 411,500 |
| MOLINA ARTURO MD | Officer | 26 Jan 2026 | Option execute | 5,000 | - | - |
| PATEL DINESH V PH D | Officer | 26 Jan 2026 | Sell (-) | 24,890 | 82.30 | 2,048,447 |
| PATEL DINESH V PH D | Officer | 26 Jan 2026 | Option execute | 24,890 | - | - |
| MOLINA ARTURO MD | Officer | 23 Jan 2026 | Sell (-) | 13,151 | 83.10 | 1,092,848 |
| PATEL DINESH V PH D | Officer | 23 Jan 2026 | Disposed (-) | 6,000 | 83.10 | 498,600 |
| PATEL DINESH V PH D | Officer | 23 Jan 2026 | Sell (-) | 19,315 | 83.10 | 1,605,077 |
| PATEL DINESH V PH D | Officer | 23 Jan 2026 | Option execute | 19,315 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 |
| 05 Jan 2026 | Announcement | Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) |
| 06 Dec 2025 | Announcement | Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera |
| 27 Nov 2025 | Announcement | DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice |
| 06 Nov 2025 | Announcement | Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |